vs
Side-by-side financial comparison of Global Medical REIT Inc. (GMRE) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $38.4M, roughly 1.8× Global Medical REIT Inc.). Global Medical REIT Inc. runs the higher net margin — -16.0% vs -49.0%, a 33.0% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 9.2%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
GMRE vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.4M | $70.6M |
| Net Profit | $-6.1M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | -16.0% | -49.0% |
| Revenue YoY | 9.2% | 81958.1% |
| Net Profit YoY | -309.2% | 54.9% |
| EPS (diluted) | $-0.48 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.4M | — | ||
| Q3 25 | $37.2M | $70.6M | ||
| Q2 25 | $38.0M | — | ||
| Q1 25 | $34.6M | — | ||
| Q4 24 | $35.2M | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $34.2M | — | ||
| Q1 24 | $35.1M | — |
| Q4 25 | $-6.1M | — | ||
| Q3 25 | $-5.1M | $-34.6M | ||
| Q2 25 | $585.0K | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -16.0% | — | ||
| Q3 25 | -13.6% | -49.0% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 10.8% | — | ||
| Q4 24 | 8.4% | — | ||
| Q3 24 | 9.9% | — | ||
| Q2 24 | -5.7% | — | ||
| Q1 24 | 6.6% | — |
| Q4 25 | $-0.48 | — | ||
| Q3 25 | $-0.45 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $-0.04 | — | ||
| Q3 24 | $0.14 | — | ||
| Q2 24 | $-0.05 | — | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.1M | $490.9M |
| Total DebtLower is stronger | $1.2M | — |
| Stockholders' EquityBook value | $509.8M | $503.0M |
| Total Assets | $1.2B | $577.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.1M | — | ||
| Q3 25 | $7.1M | $490.9M | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $5.7M | — | ||
| Q2 24 | $5.0M | — | ||
| Q1 24 | $1.3M | — |
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $14.3M | — | ||
| Q4 24 | $14.4M | — | ||
| Q3 24 | $14.5M | — | ||
| Q2 24 | $14.7M | — | ||
| Q1 24 | $25.7M | — |
| Q4 25 | $509.8M | — | ||
| Q3 25 | $485.3M | $503.0M | ||
| Q2 25 | $503.2M | — | ||
| Q1 25 | $517.4M | — | ||
| Q4 24 | $534.1M | — | ||
| Q3 24 | $542.6M | — | ||
| Q2 24 | $556.4M | — | ||
| Q1 24 | $575.0M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | $577.1M | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 0.03× | — | ||
| Q3 24 | 0.03× | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.6M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.6M | — | ||
| Q3 25 | $17.6M | $-84.6M | ||
| Q2 25 | $22.1M | — | ||
| Q1 25 | $12.3M | — | ||
| Q4 24 | $70.0M | — | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $18.9M | — | ||
| Q1 24 | $14.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 37.84× | — | ||
| Q1 25 | 3.28× | — | ||
| Q4 24 | 23.83× | — | ||
| Q3 24 | 4.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.18× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
